A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.
We examined the effect of YM529, a newly developed third-generation bisphosphonate (BP), on the growth of human myeloma cell lines using the trypan blue dye exclusion test and Alamar blue assay. BPs induced inhibition of proliferation in all cell lines dose-dependently, and YM529 had a most potent growth inhibitory effect, followed by incadronate and pamidronate. Flow cytometric analysis using annexinV and 7AAD showed that YM529 most significantly induced apoptosis of all myeloma cell lines. These observations suggested that YM529 is a potent apoptosis inducer of myeloma cells, and might have some benefit not only on the improvement of bone lesions but also on survival in some myeloma patients.
Takahashi
R
R
Second Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kawaramachi-Hirokoji, Kamigyoku, Kyoto 602-8566, Japan.
Shimazaki
C
C
Inaba
T
T
Okano
A
A
Hatsuse
M
M
Okamoto
A
A
Hirai
H
H
Ashihara
E
E
Nakagawa
M
M
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects; D004164:Diphosphonates / Q000494:pharmacology*; D005434:Flow Cytometry; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology*; D000077268:Pamidronate; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; D004164:Diphosphonates; D007093:Imidazoles; C087958:YM 529; C071542:cimadronate; D000077268:Pamidronate